PCI Biotech reports successful completion of second dose group in a Phase I/II Amphinex® trial. Strong anti-tumour response observed in all patients NewsadminJanuary 19, 2010
Initiated pre-clinical trials for the use of PCI in the treatment of Bladder Cancer NewsadminDecember 3, 2009
Successful completion of the first dose group in the Phase I/II study of Amphinex® in cancer patients NewsadminOctober 19, 2009
First cancer patient included in PCI Biotech's Phase I/II trial of Amphinex® NewsadminAugust 24, 2009
PCI Biotech-led consortium awarded EUR 1.1 million grant from the EU Eurostars Programme NewsadminMarch 23, 2009